Get the Stockscreener App
3.82
3.78%
-0.15
Pre-market:
3.61
-0.21
-5.50%
Contineum Therapeutics Inc stock is traded at $3.82, with a volume of 64,403.
It is down -3.78% in the last 24 hours and down -34.14% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$3.97
Open:
$3.92
24h Volume:
64,403
Relative Volume:
0.99
Market Cap:
$114.09M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-9.0564
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
-13.38%
1M Performance:
-34.14%
6M Performance:
-77.84%
1Y Performance:
-74.22%
1-Day Range:
$3.745
$4.08
1-Week Range:
$3.69
$4.43
52-Week Range:
$3.69
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
3.82 | 114.09M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
Contineum Therapeutics Inc Stock (CTNM) Latest News
(CTNM) Investment Analysis - news.stocktradersdaily.com
JPMorgan Chase & Co. Has $416,000 Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., As Chief Medical Officer - citybiz
Geode Capital Management LLC Purchases 59,732 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development - BioSpace
Contineum Therapeutics Appoints Timothy Watkins As Chief Medical Officer And Head Of Development - marketscreener.com
Form 8-KCurrent report - ADVFN
Critical Contrast: Contineum Therapeutics (CTNM) and Its Rivals - Defense World
We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate - Yahoo Finance
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - ADVFN
(CTNM) On The My Stocks Page - news.stocktradersdaily.com
Contineum Therapeutics (CTNM) vs. Its Competitors Head-To-Head Survey - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $24.80 Consensus PT from Analysts - Defense World
Contineum Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Contineum Therapeutics Rings the Closing Bell - Nasdaq
How the (CTNM) price action is used to our Advantage - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Has $811,000 Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Charles Schwab Investment Management Inc. Buys 12,035 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - The AM Reporter
Bank of New York Mellon Corp Has $275,000 Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Long Term Trading Analysis for (CTNM) - news.stocktradersdaily.com
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - BioSpace
Analysts Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Target Price at $24.80 - Defense World
(CTNM) Investment Report - news.stocktradersdaily.com
Jones Trading Begins Coverage on Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Jones Trading Initiates Coverage of Contineum Therapeutics (CTNM) with Buy Recommendation - Nasdaq
JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target -March 13, 2025 at 08:48 am EDT - Marketscreener.com
Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24% - Yahoo Finance
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum - Eagle-Tribune
Rhumbline Advisers Acquires 2,191 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics’ (CTNM) “Overweight” Rating Reiterated at Morgan Stanley - Defense World
Robert W. Baird Cuts Contineum Therapeutics (NASDAQ:CTNM) Price Target to $16.00 - Defense World
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones - Marketscreener.com
Contineum reports Q4 EPS (56c), consensus (44c) - TipRanks
Contineum Therapeutics, Inc. SEC 10-K Report - TradingView
Objective long/short (CTNM) Report - Stock Traders Daily
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 - Marketscreener.com
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference - Business Wire
Clinical-Stage Biotech Contineum Sets Stage for Key Investor Presentation at Leerink Conference - Stock Titan
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights - Quantisnow
Contineum Therapeutics (CTNM) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Can Contineum's Upcoming Catalysts Turn The Tide In The Coming Months? - RTTNews
How To Trade (CTNM) - Stock Traders Daily
Chief Executive Officer Monia Brett P sold $1,229,463 worth of shares (38,843 units at $31.65), decreasing direct ownership by 18% to 180,683 units (SEC Form 4) - Quantisnow
Multiple Sclerosis FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight - Barchart
Contineum Therapeutics (CTNM) Projected to Post Quarterly Earnings on Wednesday - Defense World
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):